Louis Flamand
Chercheur universitaire
Axe Maladies infectieuses et immunitaires
Autres sciences de la santé
Publications
Voir tout-
article Bolduc M, Saint-Louis P, Carignan D, Garneau C, Breton Y, Pelletier M, Rancourt A, Satoh MS, Sato S, Gilbert M, Rabezanahary H, Baz M, Dubuc I, Flamand L, Leclerc D
PapMV nanoparticles: A novel pathway to SARS-CoV-2 protection, distinct from Imidazoquinolines
Nanomedicine 2025.
-
article Bayega A, Reiling SJ, Liu JL, Dubuc I, Gravel A, Flamand L, Ragoussis J
A Benchmark of methods for SARS-CoV-2 whole genome sequencing and development of a more sensitive method
Front Genet 16 2025.
-
article Flamand L, Arbuckle J, Bonnafous P, Descamps V, Hill JA, Jarrett R, Jerome K, Kaufer BB, Koide R, Komaroff AL, Medveczky P, Miura H, Mori Y, Parrish N, Pellett PE, Wood M, Yoshikawa T, Zerr DM
Endogenous human herpesviruses 6A/B
J Virol 99 (9), 2025.
Projets
- Coronavirus Variants Rapid Response Network: CoVaRR-Net, du 2021-03-01 au 2026-03-31
- Dissecting the pathological consequences of neurological infections by herpesviruses, using human iPSC-derived cultures, du 2021-04-01 au 2026-03-31
- Human herpesvirus 6 and chromosomal integration, du 2023-04-01 au 2028-03-31
- Collaboration entre les laboratoires d’Amélie Fradet-Turcotte (AFT) et Louis Flamand (LF) sur l’étude des mécanismes de réponses aux dommages à l’ADN et les infections virales, du 2023-04-24 au 2026-04-23
- National Primate Center for Pandemic Preparedness (NPCPP), du 2024-03-01 au 2028-03-31
- Pathogenic roles of platelets in sepsis, du 2020-03-01 au 2025-03-31
- COVID-19 trilogy: ARDS, inflammation and coagulopathy, du 2020-06-01 au 2024-03-31
- Pathogenesis and immune escape potential of SARS-CoV-2 variants of concern, du 2021-06-01 au 2025-03-31